Welcome to LookChem.com Sign In|Join Free

CAS

  • or
6-(Benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid is a spirocyclic chemical compound with potential pharmaceutical applications. It features a benzyl group and a carbonyl group within its structure, making it a valuable building block in the synthesis of other pharmaceutical compounds. Its unique properties and structure contribute to its importance in medicinal chemistry and drug discovery, with the potential for bioactivity that could be harnessed for therapeutic purposes.

147610-85-3

Post Buying Request

147610-85-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

147610-85-3 Usage

Uses

Used in Pharmaceutical Research and Development:
6-(Benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid is used as a building block for the synthesis of new drugs or treatment options, leveraging its unique structure and properties to contribute to the development of innovative pharmaceuticals.
Used in Medicinal Chemistry:
6-(Benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid is utilized in medicinal chemistry as a valuable tool for the design and synthesis of novel drug candidates, potentially leading to the discovery of new therapeutic agents with improved efficacy and safety profiles.
Used in Drug Discovery Efforts:
6-(Benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid is employed in drug discovery efforts to explore its potential bioactivity and therapeutic applications, with the aim of identifying new treatment options for various diseases and conditions.
Used in Bioactivity Studies:
In bioactivity studies, 6-(Benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid is investigated for its potential to interact with biological targets, which could lead to the development of new therapeutic agents with novel mechanisms of action.
Used in Drug Synthesis:
6-(Benzyloxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid is used as a key intermediate in the synthesis of pharmaceutical compounds, contributing to the creation of new drugs with potential applications across various medical fields.

Check Digit Verification of cas no

The CAS Registry Mumber 147610-85-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,7,6,1 and 0 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 147610-85:
(8*1)+(7*4)+(6*7)+(5*6)+(4*1)+(3*0)+(2*8)+(1*5)=133
133 % 10 = 3
So 147610-85-3 is a valid CAS Registry Number.

147610-85-3Relevant articles and documents

ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES

-

Paragraph 00256, (2017/06/07)

The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity particularly involved in the development and maintenance of persistent or chronic pain, and / or neurological disorders. These novel compounds are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which these ion channels are involved. The invention is also directed towards pharmaceutical formulations comprising these compounds and the uses of these compounds.

Discovery of spirofused piperazine and diazepane amides as selective histamine-3 antagonists with in vivo efficacy in a mouse model of cognition

Brown, Dean G.,Bernstein, Peter R.,Griffin, Andrew,Wesolowski, Steve,Labrecque, Denis,Tremblay, Maxime C.,Sylvester, Mark,Mauger, Russell,Edwards, Phillip D.,Throner, Scott R.,Folmer, James J.,Cacciola, Joseph,Scott, Clay,Lazor, Lois A.,Pourashraf, Mehrnaz,Santhakumar, Vijayaratnam,Potts, William M.,Sydserff, Simon,Giguère, Pascall,Lévesque, Carine,Dasser, Mohammed,Groblewski, Thierry

, p. 733 - 758 (2014/03/21)

A new series of potent and selective histamine-3 receptor (H3R) antagonists was identified on the basis of an azaspiro[2.5]octane carboxamide scaffold. Many scaffold modifications were largely tolerated, resulting in nanomolar-potent compounds in the H3R functional assay. Exemplar compound 6s demonstrated a selective profile against a panel of 144 secondary pharmacological receptors, with activity at only σ2 (62% at 10 μM). Compound 6s demonstrated free-plasma exposures above the IC50 (~50×) with a brain-to-plasma ratio of ~3 following intravenous dosing in mice. At three doses tested in the mouse novel object recognition model (1, 3, and 10 mg/kg s.c.), 6s demonstrated a statistically significant response compared with the control group. This series represents a new scaffold of H3 receptor antagonists that demonstrates in vivo exposure and efficacy in an animal model of cognition.

4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors

-

Paragraph 0318, (2013/03/26)

The present invention provides 6-5 membered fused pyridine ring compounds according to Formula I or pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

N-PIPERIDIN-4-YL DERIVATIVES

-

Page/Page column 53, (2013/04/10)

The invention relates to a N-piperidin-4-yl derivative having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same and to the use of said N-piperidin-4-yl derivatives for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, or for the treatment of uterine fibroids or other menstrual-related disorders.

SPIROCYCLOPROPYL PIPERIDINE DERIVATIVES

-

, (2009/01/20)

Disclosed herein is at least one piperidine derivative, at least one pharmaceutical composition comprising at least one piperidine derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 147610-85-3